Browsing: Quarter

This is a paid press release. Contact the press release distributor directly with any enquiries.

NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year

Pa., Aug. 12, 2026 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter ended June 30, 2026 and provided an update on recent company developments

This is a paid press release. Contact the press release distributor directly with any inquiries.